@entity740 ( @entity740 ), @entity65 , and posttransplant @entity5 are complications of conventional immunosuppression after kidney transplantation. The aim was to study feasibility of @entity3446 (SRL) maintenance monotherapy in a pilot experience. All @entity1 with SRL monotherapy of at least 6 months follow-up were included. In 19 @entity1 , age 58 (34-74) years, SRL monotherapy was introduced 98.1 (49-193) months after transplantation by withdrawing concomitant immunosuppressants from protocols already including SRL or introducing SRL and withdrawing other immunosuppressants. Follow-up is 20.0 (6-41) months. One @entity1 died from @entity157 , diagnosed before SRL monotherapy, with functioning graft. No rejections occurred. SRL trough concentration was 10.7 (4.6-16.1) microg/L. @entity1011 (1.77 [1.0-2.9] mg/dL vs. 1.68 [0.8-3.3] mg/dL after 6 months, 1.97 [0.8-4.6] mg/dL at last follow-up; P=NS). @entity644 increased tendentially (333 [67-893] vs. 890 [46-4011] mg/day). No significant changes of hemoglobin, @entity1674 , or @entity165 occurred. SRL monotherapy late after kidney transplantation is feasible in selected @entity1 .

XXXX monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation--a pilot experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity644 :: ('MESH:D011507', 'Disease') :: ['Proteinuria'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity740 :: ('MESH:D051436', 'Disease') :: ['Chronic allograft nephropathy', 'CAN'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['Creatinine'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity3446 :: (MESH:D020123,Chemical) :: ['Sirolimus']
